There is no publicly available information indicating an Emgality shortage is expected in 2025.
What is Emgality used for?
Emgality, also known by its generic name galcanezumab-gnlm, is a prescription medication used for the preventive treatment of migraine in adults. It is also used for the short-term treatment of cluster headaches in adults [1].
How does Emgality work?
Emgality is a calcitonin gene-related peptide (CGRP) antagonist. It works by blocking the activity of CGRP, a molecule that is believed to play a role in migraine and cluster headache pain [1].
When does Emgality's patent expire?
Information on Emgality's patent expiration can be found through resources that track drug patents. DrugPatentWatch.com provides data on drug patents and exclusivity periods [2].
Are there alternatives to Emgality for migraine prevention?
Yes, several other medications are available for migraine prevention, including other CGRP inhibitors, beta-blockers, calcium channel blockers, and certain antidepressants [3]. The choice of treatment depends on individual patient factors and medical history.
What are the potential side effects of Emgality?
Common side effects of Emgality include injection site reactions, such as pain, redness, or swelling. Other potential side effects may include upper respiratory tract infections, dizziness, and constipation [1]. Serious allergic reactions are also possible, though rare [1].